

KRYSTAL INTEGRATED SERVICES LIMITED
(FORMERLY KNOWN AS KRYSTAL INTEGRATED SERVICES PRIVATE LIMITED)



January 21, 2025

KISL/CS/SE/129/2024-25

The Department of Corporate Services BSE Limited General Manager Department of Corporate Services Floor 25, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001 Scrip Code: 544149	National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051 Scrip Symbol: KRYSTAL
--	--

Dear Sir/Madam,

Sub.: Newspaper Publication - Disclosure under Regulation 30 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Pursuant to Regulation 30 read with Schedule III Part A Para A and Regulation 47 of SEBI Listing Regulations and SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, we hereby submit copies of extracts of the Un-Audited Financial Results of the Company for the quarter and nine months ended December 31, 2024, as approved by the Board of Directors at their meeting held on Monday, January 20, 2025, as published in "Financial Express" in English language newspaper and in "Mumbai Lakshadeep" in Regional language (Marathi) newspaper today, i.e. Tuesday, January 21, 2025.

The advertisement also includes a Quick Response code and the web link to access complete financial results for the said period. The above information is also available on website of the Company at www.krystal-group.com.

This is for your information and records.

Thanking You,

**For Krystal Integrated Services Limited
(Previously known as Krystal Integrated Services Private Limited)**

Stuti Maru
Company Secretary & Compliance Officer
Membership Number: A45257

INTERNATIONAL TRAVEL HOUSE LIMITED				
Regd. office : 'Travel House' T-2, Community Centre, Sheikh Sarai, Phase-I, New Delhi-110 017				
CIN : L63040DL1981PLC011941				
Tel : 91-11-26017808 E-mail : Investor_TH@ith.co.in Website : www.internationaltravelhouse.in				
Extract of Unaudited Financial Results for the Quarter and Nine Months ended 31st December, 2024				
Sl. No.	Particulars	₹ in Lakhs		
		3 months ended 31.12.2024	Nine Months ended 31.12.2024	Corresponding 3 months ended 31.12.2023
1	Total Income from Operations	5,973.90	17,941.09	5,468.95
2	Net Profit for the period (before tax and Exceptional items)	728.42	2,623.89	664.74
3	Net Profit for the period before tax (after Exceptional items)	728.42	2,623.89	664.74
4	Net Profit for the period after tax (after Exceptional items)	538.26	1,952.06	493.79
5	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	526.31	1,916.19	482.75
6	Equity Share Capital	799.45	799.45	799.45
7	Earnings Per Share (of 10/- each) (not annualised):			
	1. Basic (₹) :	6.74	24.42	6.17
	2. Diluted (₹) :	6.74	24.42	6.17

Notes:

a) The above is an extract of the detailed format of the Statement of Unaudited Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Statement of Unaudited Financial Results and this extract were reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on 20th January, 2025. The full format of the Statement of Unaudited Financial Results are available on the Company's website (www.internationaltravelhouse.in) and on the website of BSE Limited (www.bseindia.com).

b) The Limited Review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been completed and the related Report does not have any impact on the above 'Results and Notes' for the Quarter and Nine Months ended 31st December, 2024 which needs to be explained.

For and on behalf of the Board

Dated : 20th January, 2025
Place : Gurugram

Sd/-
Ashwin Moodliar
Managing Director

Sd/-
Gunjan Chadha
Chief Financial Officer



Nippon India Mutual Fund
Wealth sets you free

Nippon Life India Asset Management Limited
(CIN - L65910MH1995PLC220793)

Registered Office: 4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W), Mumbai - 400 013. Tel No. +91 022 6808 7000
Fax No. +91 022 6808 7097 • mf.nipponindia.com

Record Date
January 23, 2025*

NOTICE NO. 71

Notice is hereby given that the Trustee of Nippon India Mutual Fund ("NIMF") has approved the following Distribution on the face value of Rs. 10/- per unit under Income Distribution cum capital withdrawal (IDCW) option of the undernoted schemes of NIMF, with January 23, 2025 as the record date:

Name of the Scheme(s)	Amount of Distribution (₹ per unit)*	NAV as on January 17, 2025 (₹ per unit)
Nippon India Vision Fund - IDCW Option	5.50	67.2761
Nippon India Vision Fund - Direct Plan - IDCW Option	6.00	75.6311
Nippon India Consumption Fund - IDCW Option	3.00	39.9483
Nippon India Consumption Fund - Direct Plan - IDCW Option	4.00	59.8806

*Income distribution will be done, net of tax deducted at source, as applicable.
#or the immediately following Business Day if that day is a non-business day

Pursuant to payment of dividend/IDCW, the NAV of the Schemes will fall to the extent of payout, and statutory levy, if any. The IDCW payout will be to the extent of above mentioned Distribution amount per unit or to the extent of available distributable surplus, as on the Record Date mentioned above, whichever is lower.

For units in demat form : IDCW will be paid to those Unitholders/Beneficial Owners whose names appear in the statement of beneficial owners maintained by the Depositories under the IDCW Plan/Option of the Schemes as on record date.

All unit holders under the IDCW Plan/Option of the above mentioned schemes, whose names appear on the register of unit holders on the aforesaid record date, will be entitled to receive the IDCW.

For Nippon Life India Asset Management Limited
(Asset Management Company for Nippon India Mutual Fund)
Sd/-
Authorised Signatory

Mumbai
January 20, 2025



Good gets better

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

THE BUSINESS DAILY.



FOR DAILY BUSINESS.

financialexpress.com

KRYSTAL INTEGRATED SERVICES LIMITED

Registered Office: Krystal House, 15A/17, Shivaji Fort CHS, Duncan Causeway Road, Mumbai -400 022
CIN: L74920MH2000PLC129827, Tel. No.: +9122 4353 1234, +9122 4747 1234
Website : www.krystal-group.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED DECEMBER 31, 2024

(All Amounts are ₹ in Millions unless otherwise stated)

Sr. No.	Particulars	STANDALONE						CONSOLIDATED					
		QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED		QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED	
		31 st Dec 2024	30 th Sept 2024	31 st Dec 2023	31 st Dec 2023	31 st Dec 2023	31 st March 2024	31 st Dec 2024	30 th Sept 2024	31 st Dec 2023	31 st Dec 2023	31 st Dec 2023	31 st March 2024
1	Total income from operations (net)	2,568.97	2,461.83	2,730.26	7,463.16	7,110.50	9,847.26	2,763.73	2,661.57	2,830.74	7,996.83	7,346.82	10,268.49
2	Net Profit (+) / Loss (-) for the period (before tax, exceptional and / or extraordinary items)	161.60	155.55	151.79	479.73	410.05	561.75	170.78	163.05	156.75	498.59	411.90	575.52
3	Net Profit (+) / Loss (-) for the period before tax (after exceptional and / or extraordinary items)	161.60	155.55	151.79	479.73	410.05	561.75	170.78	163.05	156.75	498.59	411.90	575.52
4	Net Profit (+) / Loss (-) for the period after tax (after exceptional and / or extraordinary items)	144.42	144.11	124.44	441.49	334.04	482.29	151.49	151.34	128.22	455.82	334.07	490.69
5	Total Comprehensive income for the period [Comprising Profit (+) / Loss (-) for the period (after tax) and Other Comprehensive Income (after tax)]	142.78	142.85	124.69	440.44	331.19	486.22	151.85	150.32	128.39	455.16	331.15	494.43
6	Paid-up equity share capital (Face Value per share Rs.10/-)	139.72	139.72	115.24	139.72	115.24	139.72	139.72	139.72	115.24	139.72	115.24	139.72
7	Reserve (excluding Revaluation) Reserves as shown in Audited Balance Sheet of previous accounting year	-	-	-	-	-	3,584.33	-	-	-	-	-	3,622.50
8	Earnings Per Share (EPS)												
	Basic (not annualised) (Absolute Value)	10.34	10.31	10.80	31.60	28.99	41.61	10.84	10.83	11.04	32.51	28.88	42.30
	Diluted (not annualised) (Absolute Value)	10.34	10.31	10.80	31.60	28.99	41.61	10.84	10.83	11.04	32.51	28.88	42.30

Notes:

- The above is an extract of the detailed format of unaudited consolidated and standalone financial results for 3rd quarter of F.Y.2024-25 filed by the Company with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The above results have been reviewed by the Audit Committee on January 20, 2025 and approved by the Board of Directors at their meeting held on January 20, 2025. The Statutory Auditors have expressed an unmodified opinion on these results.
- Previous period's/year's figures have been regrouped/reclassified wherever necessary to conform to current period's classification.
- The full format of the consolidated and standalone financial results for 3rd quarter of F.Y.2024-25 are available on the Stock Exchange websites. (www.bseindia.com and www.nseindia.com) and also on Company's website at <https://krystal-group.com/investor/> and can also be accessed by scanning the Quick Response code available below.

For & on behalf of the Board of Directors
Sd/-
(Sanjay Suryakant Dighe)
CEO & Whole-time Director
DIN: 02042603

Place : Mumbai
Date : January 20, 2025

I. LITIGATION INVOLVING OUR COMPANY

(a) Outstanding litigation proceedings against our Company

(i) Criminal Proceedings- Nil

(ii) Actions by statutory or regulatory authorities

Except as disclosed below, there are no outstanding statutory or regulatory actions involving our Company, as on the date of this Information Memorandum.

a. The Labour Officer and Duty Assessing Officer, Government of Karnataka issued a show-cause notice to our Company under the Building and Other Construction Workers' Welfare Cess Act, 1996 ("BOCW Act") and the Building and Other Construction Workers' Welfare Cess Rules, 1998 on May 20, 2024, seeking certain documents and demanding payment of labour welfare cess under the said BOCWC Act in respect of construction of manufacturing facility at Unit II. The documents were to be previously submitted by September 30, 2022. As these documents were not submitted within time, this show cause notice was issued. The show cause notice demanded the documents to be submitted within seven days from receipt of the said notice. Our Company submitted its response on May 30, 2024. The payment of the welfare cess is pending with meetings being held with the concerned authority.

(iii) Tax proceedings

Except as disclosed below, there are no outstanding direct or indirect tax proceedings against our Company, as on the date of this Information Memorandum:

Sr.No.	Type of Tax	Number of Cases	Approximate amount demanded/ in dispute (in ₹ million)
1.	Direct Tax	10	847.03
2.	Indirect Tax	1	29.44
	Total	11	876.48

(iv) Material civil litigation- Nil

(b) Outstanding litigation proceedings by our Company

(i) Criminal Proceedings- Nil

(ii) Material civil litigation- Nil

II. LITIGATION INVOLVING OUR DIRECTORS

(a) Outstanding litigation proceedings against our Directors

(i) Criminal Proceedings- Nil (ii) Actions by statutory or regulatory authorities- Nil

(iii) Tax proceedings

Except for the tax proceedings involving Arun Kumar Pillai as disclosed below, there are no outstanding direct or indirect tax proceedings against our Directors, as on the date of this Information Memorandum:

Sr.No.	Type of Tax	Number of Cases	Approximate amount demanded/ in dispute (in ₹ million)
1.	Direct Tax	6	1,530.44
2.	Indirect Tax	Nil	Nil
	Total	6	1,530.44

(iv) Material civil litigation- Nil

(b) Outstanding litigation proceedings by our Directors

(i) Criminal Proceedings- Nil (ii) Material civil litigation- Nil

III. LITIGATION INVOLVING OUR PROMOTERS

(a) Outstanding litigation proceedings against our Promoters

(i) Criminal Proceedings- Nil (ii) Actions by statutory or regulatory authorities- Nil

(iii) Tax proceedings

Except as disclosed below, there are no outstanding direct or indirect tax proceedings against our Promoters, as on the date of this Information Memorandum:

Sr.No.	Type of Tax	Number of Cases	Approximate amount demanded/ in dispute (in ₹ million)
A. Arun Kumar Pillai			
1.	Direct Tax	6	1530.44
2.	Indirect Tax	Nil	Nil
	Total (A)	6	1530.44
B. Karuna Business Solutions LLP			
1.	Direct Tax	6	Nil
2.	Indirect Tax	Nil	Nil
	Total (B)	6	Nil

C. Tenshi Pharmaceuticals Private Limited

1.	Direct Tax	5	8.43
2.	Indirect Tax	Nil	Nil
	Total (C)	5	8.43
	Total (A + B + C)	17	1,538.87

(iv) Material civil litigation- Nil

(b) Outstanding litigation proceedings by our Promoters

(i) Criminal Proceedings- Nil

(ii) Material civil litigation- Nil

IV. LITIGATION INVOLVING OUR SUBSIDIARIES

(a) Outstanding litigation proceedings against our Subsidiaries

(i) Criminal Proceedings- Nil

(ii) Actions by statutory or regulatory authorities- Nil

(iii) Tax proceedings Nil

(iv) Material civil litigation

Except as disclosed below, there are no material outstanding civil proceedings against our Subsidiaries, as on the date of this Information Memorandum:

- Prestige Biopharma Limited (the "Claimant") initiated arbitration proceedings vide a notice of arbitration dated June 5, 2023, against Biolexis Pte. Ltd., a step-down Subsidiary of our Company, and Enso Healthcare DMCC ("Enso") (collectively, the "Respondents") in accordance with the applicable arbitration rules of the Singapore International Arbitration Centre (the "SIAC Rules"). A contract manufacturing agreement ("CMA") had been entered into by the Claimant and the Respondents for the manufacture and supply of Sputnik Light, a Covid-19 vaccine. As per the CMA, Biolexis Pte. Ltd., was required to supply the raw materials, information and technology to the Claimant for the manufacture of the vaccine and Enso was to coordinate with Human Vaccine and/or Russia Direct Investment Fund, for the procurement of said raw materials. The Claimant sent a letter to Biolexis Pte Ltd. on January 3, 2023, in which the Claimant alleged that Biolexis Pte. Ltd. had deliberately withheld the required raw materials, information and technology so as to enable our Company to manufacture the vaccine instead and that Enso had been a part of such conspiracy. Subsequently, good faith negotiations and mediation were initiated in accordance with the terms of the CMA. The failure of the mediation led to the invocation of the arbitration clause and a statement of claim was filed on February 29, 2024, by the Claimant for an amount of US \$136.32 million (approximately ₹ 11,460 million) before a sole arbitrator. Thereafter, Biolexis Pte. Ltd. filed a counter claim in addition to its statement of defence, for an amount of US \$13.63 million (approximately ₹ 1,146 million) which had been paid as an advance amount as per the terms of the CMA. This amount was allegedly guaranteed to be refunded by the Claimant upon the occurrence of certain events set out in the CMA. The allegations made by the Claimant were denied. The arbitration proceedings are currently pending before the sole arbitrator appointed in accordance with the SIAC Rules.

(b) Outstanding litigation proceedings by our Subsidiary

(i) Criminal Proceedings- Nil

(ii) Material civil litigation- Nil

V. LITIGATION INVOLVING OUR GROUP COMPANIES: Nil

Q) Regulatory Action, if any -disciplinary action taken by SEBI or Stock Exchanges against the Promoters in last 5 financial years: Nil

R) Brief details of outstanding criminal proceedings against the Promoters: Nil

S) Particulars of high, low and average prices of the shares of the listed transferor entity during the preceding three years:

Year	BSE			NSE		
	High	Low	Average market price of Equity Shares for the year	High	Low	Average market price of Equity Shares for the year
2023-24	838.10	287.90	521.32	838.60	287.40	521.44
2022-23	392.20	263.45	325.08	392.00	263.35	325.17
2021-22	946.80	304.50	597.73	947.00	304.20	597.68

T) Any material development after the date of the balance sheet;

except as stated below, no circumstances have arisen, since the date of the latest financial information disclosed in this Information Memorandum (i.e. September 30, 2024), which materially and adversely affect or are likely to affect our operations, our trading or profitability or the value of our assets or our ability to pay our liabilities within the next 12 months:

I. Approval for Scheme of Arrangement

The NCLT approved the Scheme on November 14, 2024 (the "Order") and our Company received the certified true copy of the Order on November 26, 2024, and the Scheme was made effective on November 27, 2024, by filing of certified true copy of the Order with the Registrar of Companies, Mumbai.

Pursuant to the Scheme and with effect from the Appointed Date in accordance with the provisions of the Companies Act, the provisions of Section 2(19AA) of the Income Tax Act, the Demerged Undertakings along with all its assets, liabilities, contracts, loan, debentures, duties and arrangements, obligations and permits has been demerged from Demerged Company 1 & Demerged Company 2 respectively and transferred to and vested in our Company as a going concern, so as to become the assets, liabilities, contracts, arrangements, loan, debentures and permits of our Company with effect from Appointed Date.

In view of the above, the Demerged Company 1 & the Demerged Company 2 had fixed December 6, 2024, as the Record Date for the purpose of determining the eligible shareholders holding equity shares of the Demerged Company 1 & Demerged Company 2 entitled to receive the new shares of our Company, whose name is recorded in the register of members and records of the depository as members of the Demerged Company 1 & Demerged Company 2 as on the Record Date.

In consideration of the demerger of the Demerged Undertakings into our Company pursuant to the provisions of the Scheme, our Board of Directors at their meeting dated December 10, 2024, approved the allotment of 77,700,922 fully paid-up Equity Shares of ₹ 1 each to the eligible shareholders of the Demerged Company 1 & Demerged Company 2. We have issued and allotted, on a proportionate basis to each shareholder of Demerged Company as below:

- For Strides Pharma Science Limited: one share for every two shares: 46,081,357 equity shares of ₹ 1 each of our Company for 92,162,714 equity shares of ₹ 10 each of Demerged Company 1.
- For Steriscience Specialities Private Limited: 1,515 shares for every one share: 31,619,565 equity shares of ₹ 1 each of our Company for 20,871 equity shares of ₹ 10 each of Demerged Company 2.

ii. Capital infusion of ₹ 8,010.61 million through issue of Equity shares in our Company;

Our Company has raised funds by way of following issuances:

- Issue of 2,272,687 fully paid-up equity shares having a face value of ₹ 1 each and at a premium of ₹ 1,275 each for cash consideration on a private placement basis on November 21, 2024; and
- Issue of 4,005,222 fully paid-up equity shares having a face value of ₹ 1 each and at a premium of ₹ 1,275 each for cash consideration on a private placement basis on November 22, 2024.

The above mentioned transactions aggregate to ₹ 8,010.61 million.

iii. Redemption of Non-Convertible Debentures (NCDs) amounting to ₹ 2,000 million:

On November 28, 2024, our Company redeemed 20,000 secured, rated, listed, redeemable non-convertible debentures aggregating up to ₹ 2,000 million.

U) Such other information as may be specified by the Board from time to time- Nil

Notes:

- The average stock price is the simple average of closing prices for all trading days of a particular financial year.
- Hon'ble NCLT, Mumbai bench vide an order dated November 14, 2024 (certified true copy of the order was Received on November 26, 2024) approved the Scheme of Arrangement. Pursuant to the Scheme of demerger, the Spinning Division is transferred to and vested into our Company. The Effective Date of the Scheme is November 27, 2024 with April 1, 2024 as the Appointed Date.

For OneSource Specialty Pharma Limited
Sd/-
Neeraj Sharma
Managing Director

Date : January 21, 2025
Place : Bengaluru

